Rebyota denied as non-formulary by Cigna?

Cigna's specific coverage criteria for rebyota are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denied Rebyota as Non-Formulary — and Why You Can Appeal

Rebyota (fecal microbiota, live-jslm) is an FDA-approved therapy for prevention of recurrent Clostridioides difficile (C. diff) infection. A non-formulary denial means the drug is not included on Cigna's covered drug list for your specific plan, or is placed at a tier that makes it subject to non-formulary cost-sharing rules. Formularies are updated periodically and may not always reflect the current availability of newer FDA-approved agents. Importantly, a non-formulary status does not mean coverage is impossible — a formulary exception (also called a medical exception or coverage exception) is available for most plans when no formulary alternative is appropriate for your condition.

## Why This Denial Is Appealable

Cigna, like all major insurers, has a formulary exception process that allows coverage of non-formulary drugs when a covered formulary alternative is clinically inappropriate, ineffective, or contraindicated for a specific patient. For recurrent C. diff, the relevant clinical question is whether any formulary alternative can address your specific history and presentation. Your prescriber can document why no formulary alternative is appropriate and request a formulary exception concurrently with or as part of your appeal.

## Federal Appeal Framework

• Formulary exception request: File simultaneously with or before the formal internal appeal; many plans resolve these at the exception stage without a full appeal.
• Internal appeal: File within the deadline on your denial notice. Under ERISA Section 503 and ACA Section 2719 requirements, you are entitled to review and the criteria Cigna applied.
• External review: Available after exhausting internal remedies. The standard window is approximately 4 months from the final internal denial.
• Expedited review: Request if your health would be seriously jeopardized by delay.

## Appeal Timeline

1. Request Cigna's formulary exception form and the current formulary with all listed alternatives. 2. Have your prescriber review each formulary alternative and document why each is not appropriate for you. 3. Submit the exception request and internal appeal together. 4. If denied, request external review promptly.

## Documentation to Gather

• Diagnosis and history: Lab-confirmed C. diff episodes with dates and treatment courses.
• Formulary alternative evaluation: Records showing any formulary alternatives were tried and failed, or your prescriber's documented clinical rationale for why they cannot be used.
• Prescriber medical-necessity letter: Should explain the distinct mechanism and FDA-approved indication of Rebyota, why it is appropriate for your case, and why formulary alternatives are inadequate.
• Clinical severity documentation: Notes documenting the burden of recurrent C. diff on your health.

## Criteria-Mapping Structure

Obtain Cigna's formulary exception criteria. Map each to your documentation:

| Exception Criterion | Supporting Evidence | |---|---| | Non-formulary drug has FDA approval for the indication | Prescribing information confirming approval | | Formulary alternatives tried or contraindicated | Treatment history or prescriber clinical rationale | | No formulary alternative is clinically appropriate | Prescriber letter addressing each listed alternative |

Formulary exceptions for FDA-approved drugs with a well-documented clinical rationale and no appropriate alternatives have a meaningful success rate, especially when supported by a detailed specialist letter.